Find out how market forces will dictate the trajectory of house prices in the next few months
DGAP-News: Dermapharm Holding SE / Key word(s): AGM/EGM
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 2.17 per share
01.06.2022 / 16:26
The issuer is solely responsible for the content of this announcement.

Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 2.17 per share
           – Board of Management and Supervisory Board actions ratified with large majority
– Shareholders resolve dividend payment of EUR 2.17 per share
– Distribution ratio: approximately 55% of consolidated net profit
– Previous Supervisory Board members reappointed
– 2022 outlook confirmed
Grünwald, 1 June 2022 – Dermapharm Holding SE (“Dermapharm”), a rapidly growing manufacturer of branded pharmaceuticals, today successfully held its 2022 Annual General Meeting. 80.43% of the share capital was in attendance at the virtual Annual General Meeting. The majority of shareholders approved the management’s proposals under every agenda item.
The Annual General Meeting ratified the actions of the Board of Management and of the Supervisory Board for financial year 2021 with a 98.54% and 92.26% majority of votes cast, respectively. At the recommendation of the Board of Management, the Annual General Meeting resolved to distribute a dividend of EUR 2.17 per share. The total distribution amounts to EUR 116.8 million, representing a distribution ratio of approximately 55%.
The election of the Supervisory Board was also held at Annual General Meeting, and the three present members, Mr Wilhelm Beier, Dr Erwin Kern and Mr Lothar Lanz, were reappointed. The term of office of all Supervisory Board members expires at the end of the 2026 Annual General Meeting.
Grant Thornton AG Wirtschaftsprüfungsgesellschaft was once again elected to serve as auditors. The detailed results of the voting for each agenda item are available in the Annual General Meeting section of the Company website
In their retrospective on financial year 2021, the Board of Management and the Supervisory Board highlighted the Company’s extraordinary performance, which had proved a highly challenging feat to achieve, particularly in the second half of the year, in light of supply bottlenecks and price increases. With this in mind, they expressed their gratitude to all employees for their tireless efforts in 2021. The Board of Management concluded by providing an outlook for the remainder of 2022.
“This past year, 2021, was the most successful year in Dermapharm’s 30-year history. Everyone in our Group can be extremely proud of this achievement. Even in the face of difficult conditions, we are looking to remain on our growth trajectory in 2022. We have already proven in the past that we can do this,” said Dr Hans-Georg Feldmeier, Chairman of the Board of Management of Dermapharm Holding SE.
Based on the course of Dermapharm’s business to date in 2022, the Board of Management confirmed the outlook for the full year, which forecast an increase of 10–13% in consolidated revenue and of 3–7% in consolidated EBITDA.

Company profile
Dermapharm – Pharmaceutical Excellence “Made in Germany”
Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals. Founded in 1991, the Company is based in Grünwald near Munich. The Company’s integrated business model comprises in-house development, production and the distribution of brand-name products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe (primarily in Germany) and the United States.
In the “Branded pharmaceuticals and other healthcare products” segment, Dermapharm has approximately 1,300 marketing authorisations with more than 380 active pharmaceutical ingredients. Dermapharm’s portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany.
In the “Herbal extracts” segment, Dermapharm can tap the expertise of the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries. At the beginning of 2022, the segment was expanded to include Germany-based C³ Group, which develops, manufactures and markets synthetic cannabinoids. C³ Group is the market leader for dronabinol in Germany and Austria.
Dermapharm’s business model also includes the “Parallel import business” segment that operates under the “axicorp” brand. Based on revenue, axicorp was among the top five parallel import companies in Germany in 2021.
With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, Dermapharm has continuously optimised its business over the past 30 years and sought external growth opportunities in addition to organic growth. Dermapharm is firmly committed to continuing on this profitable growth course in the future.
Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 – 64186-233

01.06.2022 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
+49 (0)89 64 86-0
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID:

End of News
DGAP News Service
German prosecutors raided asset manager DWS and the headquarters of its majority owner Deutsche Bank on Tuesday over allegations of misleading investors about "green" investments, the prosecutors said. DWS and Deutsche Bank said the asset manager had cooperated with regulators and authorities in the past and would continue to do so.
Global Personal Development Market Global Personal Development Market Dublin, June 01, 2022 (GLOBE NEWSWIRE) — The "Personal Development Market Size, Share & Trends Analysis Report by Instrument (Books, e-Platforms, Personal Coaching/Training), by Focus Area, by Region, and Segment Forecasts, 2022-2030" report has been added to's offering. The global personal development market size is estimated to reach USD 67.02 billion by 2030, growing at a CAGR of 5.5% from 2022 to 20
£95.15 to fill up an average family car after latest rise in fuel costs, says RAC
People could soon be eating grass instead of steaks and cheese as British scientists develop ways to turn pasture into food.
According to the RAC’s Fuel Watch data, a litre of unleaded rose from 162.87p at the start of May to 174.02p by the close.
A look at investment trusts that have been delivering since before the Queen ascended to the throne.
FTSE 100 reshuffle could see six stocks changing places
Major companies in the crop production market include Cargill Incorporated, Bayer AG, Bunge Limited, Corteva Inc, UPL Limited, Total Produce plc, Fresh Del Monte Produce Inc, Grupo Amaggi, Olam International, and Seaboard Corporation.New York, May 31, 2022 (GLOBE NEWSWIRE) — announces the release of the report "Crop Production Global Market Report 2022" – The global crop production market is expected to grow from $4,763.91
The Renal Biomarkers market was valued at USD 1,041. 12 million in 2021, and it is expected to reach USD 1,662. 54 million by 2027, registering a CAGR of 7. 76% during the period of 2022-2027.New York, June 01, 2022 (GLOBE NEWSWIRE) — announces the release of the report "Renal Biomarkers Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)" – Due to the COVID-19 pandemic, the footfall in the hospitals and d
FRANKFURT (Reuters) -German companies Uniper and RWE have paid for Russian gas under a new scheme proposed by Moscow, in a bid to ensure continued supply of the fuel that is critical to Europe's top economy. Russia's payment scheme, which involves setting up accounts that would be paid in euros and then swapped for roubles, has exposed cracks in Europe's united response towards Russia for its February invasion of Ukraine, with some countries refusing to pay and others finding ways to comply. Germany greatly depends on Russian gas, which accounted for more than half of all imports of the fuel last year.
Rooftop at Radisson Blu 1882 Hotel, Barcelona Sagrada Famili Rooftop at Radisson Blu 1882 Hotel, Barcelona Sagrada Famili Restaurant at Radisson Blu 1882 Hotel, Barcelona Sagrada Familia Restaurant at Radisson Blu 1882 Hotel, Barcelona Sagrada Familia Pool at Radisson Blu 1882 Hotel, Barcelona Sagrada Familia Pool at Radisson Blu 1882 Hotel, Barcelona Sagrada Familia Lobby at Radisson Blu 1882 Hotel, Barcelona Sagrada Familia Lobby at Radisson Blu 1882 Hotel, Barcelona Sagrada Familia Terrace at
The BRC warned shop price rises 'to get worse before it gets better' as households struggle amid the cost of living crisis.
Nine distinct homes have made it into the grand final of Scotland's Home Of The Year 2022, chosen by judges Kate Spiers, Anna Campbell-Jones and Michael Angus.
US Text-to-Speech Market US Text-to-Speech Market Dublin, May 31, 2022 (GLOBE NEWSWIRE) — The "US Text-to-Speech Market (2022-2027) by Offering, Deployment Mode, Voice Type, Organization Size, Language, Vertical., Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to's offering. The US Text-to-Speech Market is estimated to be USD 473.1 Mn in 2022 and is projected to reach USD 998.82 Mn by 2027, growing at a CAGR of 16.12%.Market dy
Strong GDP figures and growth is disguising what’s really happening: a shift to an economy where workers get less and less of their fair share
Major companies in the metal market include POSCO, Baoshan Iron & Steel Co. Ltd, ArcelorMittal S. A. , Nippon Steel & Sumitomo Metal Corporation, Jiangxi Copper Company, JFE Holdings Inc. , Glencore International, Hyundai Steel Company, Nucor Corp, and TATA Steel Group.New York, May 31, 2022 (GLOBE NEWSWIRE) — announces the release of the report "Metal Global Market Report 2022" – The global metal market is expected to grow
Australia is poised for a third year of near-record wheat production in 2022 as good weather boosts planting across its grain belt, easing concerns over tight global inventories. World wheat supplies have tightened after Russia's invasion of Ukraine earlier this year cut off shipments from one of the top exporting regions, sending grain prices sharply higher and fuelling fears of a global food crisis. Farmers in Australia, which emerged as the world's second largest wheat exporter in 2021/22, have nearly finished this year's wheat planting on about 14.45 million hectares (35.7 million acres), an all-time high, encouraged by red-hot prices and ideal growing conditions, according to estimates from brokerage IKON Commodities.
Global Complaint Management Software Market Global Complaint Management Software Market Dublin, June 01, 2022 (GLOBE NEWSWIRE) — The "Complaint Management Software Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to's offering. The global complaint management software market reached a value of US$ 1.98 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 3.99 Billion by 202
The Paris Airport authority, which manages Charles de Gaulle and Orly airports, and the Eurostar rail service both warned on Wednesday of major disruption to travellers, adding to pressure on holidaymakers already facing delays across Europe. The Paris Airport body sent a message on its Twitter account saying that software problems were impacting border controls checks, and this in turn would lead to delays. Eurostar, which runs train services linking London to Paris, also issued a similar warning.
Global Primary Immunodeficiency Therapeutics Market 2022-2026 The analyst has been monitoring the primary immunodeficiency therapeutics market and it is poised to grow by $ 3. 13 bn during 2022-2026, accelerating at a CAGR of 7.New York, May 31, 2022 (GLOBE NEWSWIRE) — announces the release of the report "Global Primary Immunodeficiency Therapeutics Market 2022-2026" – 73% during the forecast period. Our report on the prima


By admin

Leave a Reply

Your email address will not be published. Required fields are marked *